Guardant 360® Liquid Biopsy Advances Clinical Trial Enrollment

Dr. Justin Odegaard, VP of Clinical Development at Guardant Health discusses a new study published in “Nature Medicine” (Oct 2020) which finds that the Guardant360® liquid biopsy rapid blood test is not only concordant to tissue biopsy, but more than doubles clinical trial enrollment and achieves similar treatment response and survival rates in patients with advanced gastrointestinal cancer.

Dr. Justin Odegaard is currently Vice President of Clinical Development at Guardant Health, where he leads Guardant’s clinical trials and companion diagnostic development. Prior to Guardant, Dr. Odegaard was Director of molecular pathology at Lifecode and adjunct attending faculty at Stanford University Hospital. He received his PhD in immunology and his MD from Stanford University, where he later trained in and practiced both surgical pathology and molecular pathology.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.